News Center » Pumas-AI Launches Pumas Software to Advance Drug Development, Patient Care
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
PumaBiotech (@pumabiotech) / X
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology's Neratinib attempts to break new ground in HER2-positive Breast Cancer market - Clinical Trials Arena
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K) -December 16, 2022 at 04:18 pm EST | MarketScreener
Caligor supporting Puma's expanded access program
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology - Crunchbase Company Profile & Funding
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Jeff J. Ludwig - Chief Commercial Officer at Puma Biotechnology | The Org
Puma Biotechnology NPS & Customer Reviews | Comparably
Puma Biotechnology, Inc. | CDISC
Carlos Estrada - Vice President R&D Quality Assurance - Puma Biotechnology, Inc. | LinkedIn
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Business Wire
Puma Biotechnology Surpasses Expectations with Impressive Q2 Financial Results - Best Stocks
Pumas Products Suite
Puma Biotechnology falls more than 20%
Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High | Investor's Business Daily
